Recombinant Antigen expertise
BBI now has an extensive range of options for new recombinant antigen expression development and scale up. Our site in Sittingbourne has a track record of successfully developing E.coli and Pichia products and the team in Freiburg also offer the Baculovirus sf9 insect cell system.
BBI’s experienced team of scientists will look at the sequence and three-dimensional structure to define the optimal approach for clients requiring new biomarkers. The custom proposal will outline the expression trials and purification work needed. We will then offer a range of characterisation options including use of patient samples to assess commutability.
For antigens designed for serological applications BBI will offer a range of methodologies including line assays and ELISA. Should a client require one of our antigens in a specific formulation, or with an additional label such as Streptavidin if this is not available off the shelf, BBI can customise its current range of products.